GSK chief scientist and Vir CEO on clinical trial for Covid-19 antibody drug

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic. Hal Barron, GlaxoSmithKline’s chief scientific officer, and George Scangos, CEO of Vir Biotechnology, join "Squawk on the Street" to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC For info on the best credit cards go to CNBC Select: https://www.cnbc.com/select/best-cred... #CNBC #CNBCTV